 BOSTON, Aug. 27, 2021 GLOBE NEWSWIRE -- Aileron Therapeutics Nasdaq: ALRN, a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced a poster presentation showcasing initial findings from its ongoing study of ALRN-6924 in healthy volunteers at the International Society for Experimental Hematology ISEH 50th Annual Scientific Meeting, which is currently underway. The initial findings demonstrated that a 0.3 mgkg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in healthy, normal bone marrow cells without concurrent induction of apoptosis. The poster can be viewed on Ailerons website here. 